Terms: = Lymphoma AND MDM4, DKFZp781B1423, 4194, ENSG00000198625, RP11-430C7_1, MRP1, MDMX, MGC132766 AND Treatment
27369 results:
1.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract] [Full Text] [Related]
2. [UPLC-QE-Orbitrap-MS combined with network pharmacology to explore differential components and mechanisms of raw and scorched rhubarb for treatment of ulcerative colitis].
Sun J; Xu WJ; Zhong LY; Chen JB; Dong L
Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(7):1834-1847. PubMed ID: 38812196
[TBL] [Abstract] [Full Text] [Related]
3. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
Redmer T; Raigel M; Sternberg C; Ziegler R; Probst C; Lindner D; Aufinger A; Limberger T; Trachtova K; Kodajova P; Högler S; Schlederer M; Stoiber S; Oberhuber M; Bolis M; Neubauer HA; Miranda S; Tomberger M; Harbusch NS; Garces de Los Fayos Alonso I; Sternberg F; Moriggl R; Theurillat JP; Tichy B; Bystry V; Persson JL; Mathas S; Aberger F; Strobl B; Pospisilova S; Merkel O; Egger G; Lagger S; Kenner L
Mol Cancer; 2024 May; 23(1):114. PubMed ID: 38811984
[TBL] [Abstract] [Full Text] [Related]
4. A retrospective analysis of the incidence and risk factors of perioperative urinary tract infections after total hysterectomy.
Cao X; Tu Y; Zheng X; Xu G; Wen Q; Li P; Chen C; Yang Q; Wang J; Li X; Yu F
BMC Womens Health; 2024 May; 24(1):311. PubMed ID: 38811924
[TBL] [Abstract] [Full Text] [Related]
5. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Bender B; Li CC; Marchand M; Turner DC; Li F; Vadhavkar S; Wang B; Deng R; Lu J; Jin J; Li C; Yin S; Wei M; Chanu P
Clin Transl Sci; 2024 Jun; 17(6):e13825. PubMed ID: 38808543
[TBL] [Abstract] [Full Text] [Related]
6. Phase 1 Study of CK0801 in treatment of Bone Marrow Failure Syndromes.
Kadia TM; Huang M; Pemmaraju N; Abbas HA; Ly C; Masarova L; Yilmaz M; Lyu MA; Zeng K; Sadeghi T; Cook R; DiNardo CD; Daver N; Issa GC; Jabbour E; Borthakur G; Jain N; Garcia-Manero G; Parmar S; Flowers C; Kantarjian H; Verstovsek S
NEJM Evid; 2024 Jun; 3(6):EVIDoa2300362. PubMed ID: 38804782
[TBL] [Abstract] [Full Text] [Related]
7. Predictive Factors of Therapy-Related Cardiovascular Events in Patients with lymphoma Receiving Anthracyclines.
Lopez-Garcia A; Macia E; Gomez-Talavera S; Castillo E; Morillo D; Tuñon J; Ibañez B; Cordoba R
Med Sci (Basel); 2024 Apr; 12(2):. PubMed ID: 38804379
[TBL] [Abstract] [Full Text] [Related]
8. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
[TBL] [Abstract] [Full Text] [Related]
9. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Dupuis J; Bachy E; Morschhauser F; Cartron G; Fukuhara N; Daguindau N; Casasnovas RO; Snauwaert S; Gressin R; Fox CP; d'Amore FA; Staber PB; Tournilhac O; Bouabdallah K; Thieblemont C; André M; Rai S; Ennishi D; Gkasiamis A; Nishio M; Fornecker LM; Delfau-Larue MH; Sako N; Mule S; de Leval L; Gaulard P; Tsukasaki K; Lemonnier F
Lancet Haematol; 2024 Jun; 11(6):e406-e414. PubMed ID: 38796193
[TBL] [Abstract] [Full Text] [Related]
10. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
Kilickap S; Ozturk A; Karadurmus N; Korkmaz T; Yumuk PF; Cicin I; Paydas S; Cilbir E; Sakalar T; Uysal M; Yesil Cinkir H; Uskent N; Demir N; Sakin A; Dursun OU; Aver B; Turhal NS; Keskin S; Tural D; Eralp Y; Bugdayci Basal F; Yasar HA; Sendur MAN; Demirci U; Cubukcu E; Karaagac M; Cakar B; Tatli AM; Yetisyigit T; Urvay S; Gursoy P; Oyan B; Turna ZH; Isikdogan A; Olmez OF; Yazici O; Cabuk D; Seker MM; Unal OU; Meydan N; Okutur SK; Tunali D; Erman M;
Medicine (Baltimore); 2024 May; 103(21):e37972. PubMed ID: 38787994
[TBL] [Abstract] [Full Text] [Related]
11. Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland: A case report and literature review.
Zhong Q; Yan Y; Li S
Medicine (Baltimore); 2024 May; 103(21):e38303. PubMed ID: 38787969
[TBL] [Abstract] [Full Text] [Related]
12. Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin lymphoma or Peripheral T-Cell lymphoma: A Retrospective United States Claims Analysis.
Sano D; Liu N; Knowles S; MacEwan JP; Wang S; Wogen J; Yu KS; Lee ST
Curr Oncol; 2024 May; 31(5):2598-2609. PubMed ID: 38785476
[TBL] [Abstract] [Full Text] [Related]
13. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163
[TBL] [Abstract] [Full Text] [Related]
14. FAT1 inhibits the proliferation of DLBCL cells via increasing the m
Wang TL; Miao XJ; Shuai YR; Sun HP; Wang X; Yang M; Zhang N
Sci Rep; 2024 May; 14(1):11836. PubMed ID: 38782965
[TBL] [Abstract] [Full Text] [Related]
15. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
Li X; Wu D; Tang J; Wu Y
J Cancer Res Clin Oncol; 2024 May; 150(5):271. PubMed ID: 38780840
[TBL] [Abstract] [Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
Salem AH; Menon RM
Clin Transl Sci; 2024 May; 17(5):e13807. PubMed ID: 38778732
[TBL] [Abstract] [Full Text] [Related]
17. A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL.
Wang X; Deng Y; He G; Lai S; Li Y; Zhang S; He Y; Han Y; Zhang L; Su Y; Liu F; Yi H
Hematology; 2024 Dec; 29(1):2356300. PubMed ID: 38776229
[TBL] [Abstract] [Full Text] [Related]
18. Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.
Carlund O; Thörn E; Osterman P; Fors M; Dernstedt A; Forsell MNE; Erlanson M; Landfors M; Degerman S; Hultdin M
Clin Epigenetics; 2024 May; 16(1):68. PubMed ID: 38773655
[TBL] [Abstract] [Full Text] [Related]
19. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
Durand M; Cabaud Gibouin V; Duplomb L; Salmi L; Caillot M; Sola B; Camus V; Jardin F; Garrido C; Jego G
J Exp Clin Cancer Res; 2024 May; 43(1):148. PubMed ID: 38773631
[TBL] [Abstract] [Full Text] [Related]
20. Thyroid papillary carcinoma combined with primary follicular lymphoma: a case report.
Xu T; Wu L; Ye H; Luo S; Wang J
Diagn Pathol; 2024 May; 19(1):69. PubMed ID: 38773600
[TBL] [Abstract] [Full Text] [Related]
[Next]